Zoetis Inc.
Zoetis Reports Q3 2025 Financial Results and Updates Full-Year Guidance
Summary
Zoetis Inc. reported a 1% increase in revenue to $2.4 billion for the third quarter of 2025, achieving a 6% increase in net income to $721 million, or $1.63 per diluted share. The company also revised its full-year 2025 revenue guidance to between $9.400 billion and $9.475 billion, anticipating organic operational growth of 5.5% to 6.5%. Zoetis further narrowed its guidance for organic operational growth in adjusted net income to 5.5% to 7.0%. The company maintained its guidance for adjusted diluted earnings per share of $6.30 to $6.40 for the full year.
Profitelligence Alerts
Get alerts for ZTS
Be first to know when Zoetis Inc. files with the SEC.
Filing Categories
Advertisement
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Official SEC Documents
Advertisement